184 related articles for article (PubMed ID: 24523296)
1. Observations of urinary oxycodone and metabolite distributions in pain patients.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
[TBL] [Abstract][Full Text] [Related]
2. Urinary hydrocodone and metabolite distributions in pain patients.
Barakat NH; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Sep; 38(7):404-9. PubMed ID: 24836897
[TBL] [Abstract][Full Text] [Related]
3. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
Fang WB; Lofwall MR; Walsh SL; Moody DE
J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
[TBL] [Abstract][Full Text] [Related]
4. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
5. Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases.
Pantano F; Brauneis S; Forneris A; Pacifici R; Marinelli E; Kyriakou C; Pichini S; Busardò FP
Clin Chem Lab Med; 2017 Aug; 55(9):1324-1331. PubMed ID: 28080998
[TBL] [Abstract][Full Text] [Related]
6. Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives.
Cone EJ; Zichterman A; Heltsley R; Black DL; Cawthon B; Robert T; Moser F; Caplan YH
Forensic Sci Int; 2010 May; 198(1-3):58-61. PubMed ID: 20036472
[TBL] [Abstract][Full Text] [Related]
7. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
[TBL] [Abstract][Full Text] [Related]
8. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
[TBL] [Abstract][Full Text] [Related]
9. Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients.
Yee DA; Best BM; Atayee RS; Pesce AJ
J Anal Toxicol; 2012 May; 36(4):232-8. PubMed ID: 22511697
[TBL] [Abstract][Full Text] [Related]
10. Urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions?
Mikus G
J Anal Toxicol; 2015; 39(1):81-2. PubMed ID: 25288721
[No Abstract] [Full Text] [Related]
11. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.
Grönlund J; Saari TI; Hagelberg N; Neuvonen PJ; Olkkola KT; Laine K
Antimicrob Agents Chemother; 2011 Mar; 55(3):1063-7. PubMed ID: 21173180
[TBL] [Abstract][Full Text] [Related]
12. Response to urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2015; 39(1):80. PubMed ID: 25288719
[No Abstract] [Full Text] [Related]
13. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
[TBL] [Abstract][Full Text] [Related]
14. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine.
Moy KV; Ma JD; Morello CM; Atayee RS; Best BM
J Opioid Manag; 2014; 10(1):47-56. PubMed ID: 24604569
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
16. Uncertainty in assessing impact of drug-drug interactions on oxycodone metabolite patterns.
DePriest AZ; Puet BL; Heltsley R; Robert T; Black DL
J Anal Toxicol; 2014 Sep; 38(7):462. PubMed ID: 24986837
[No Abstract] [Full Text] [Related]
17. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
[TBL] [Abstract][Full Text] [Related]
18. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
[TBL] [Abstract][Full Text] [Related]
20. Determination of oxycodone and its major metabolites in haematic and urinary matrices: Comparison of traditional and miniaturised sampling approaches.
Protti M; Catapano MC; Samolsky Dekel BG; Rudge J; Gerra G; Somaini L; Mandrioli R; Mercolini L
J Pharm Biomed Anal; 2018 Apr; 152():204-214. PubMed ID: 29414014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
